Roche Wins InterMune, But For A Price
This article was originally published in The Pink Sheet Daily
Executive Summary
With the $8.3 billion purchase price, Roche gains InterMune’s sole drug, pirfenidone for idiopathic pulmonary fibrosis, pending at FDA with action expected Nov. 23.